Table 3.

Multivariate Proportional Hazard Models

Outcome and Covariate	Hazard Ratio	95% CI	P
All-cause mortality
Age < 70 v ≥ 70 years	1.57	1.34 to 1.84	< .0001
Race: black v other	1.07	0.84 to 1.37	.57
Tumor stage
< T3	—	—
T3	1.11	0.95 to 1.30	.20
T4	1.79	1.25 to 2.57	.002
Gleason sum: 2-6 v 7-10	1.41	1.20 to 1.66	< .0001
Prostate-specific antigen: ≤ 30 v > 30 ng/mL	1.02	0.86 to 1.20	.83
Treatment arm: I v II	0.86	0.74 to 1.01	.06
Diabetes: no v yes	1.77	1.45 to 2.16	< .0001
Weight
Tertile 1 (< 78.2 kg)	—	—
Tertile 2 (78.2-89.5 kg)	1.10	0.92 to 1.33	.30
Tertile 3 (> 89.5 kg)	1.14	0.94 to 1.38	.20
Prostate cancer mortality
Age < 70 v ≥ 70 years	0.65	0.48 to 0.87	.004
Race: black v other	1.27	0.80 to 2.02	.31
Tumor stage
< T3	—	—
T3	1.44	1.05 to 1.98	.02
T4	3.96	2.28 to 6.88	< .0001
Gleason sum: 2-6 v 7-10	1.88	1.35 to 2.63	.0002
Prostate-specific antigen: ≤ 30 v > 30 ng/mL	1.25	0.93 to 1.68	.14
Treatment arm: I v II	0.63	0.47 to 0.85	.002
Diabetes: no v yes	0.80	0.51 to 1.25	.32
Weight
Tertile 1 (< 78.2 kg)	—	—
Tertile 2 (78.2-89.5 kg)	1.25	0.85 to 1.84	.26
Tertile 3 (> 89.5 kg)	1.77	1.22 to 2.55	.002
Non–prostate cancer mortality
Age < 70 v ≥ 70 years	2.14	1.75 to 2.60	< .0001
Race: black v other	1.00	0.76 to 1.33	.99
Tumor stage
< T3	—	—
T3	0.93	0.78 to 1.12	.47
T4	0.86	0.52 to 1.43	.56
Gleason sum: 2-6 v 7-10	1.16	0.96 to 1.39	.12
Prostate-specific antigen: ≤ 30 v > 30 ng/mL	0.94	0.78 to 1.15	.57
Treatment arm: I v II	1.05	0.88 to 1.26	.57
Diabetes: no v yes	2.12	1.69 to 2.66	< .0001
Weight
Tertile 1 (< 78.2 kg)	—	—
Tertile 2 (78.2-89.5 kg)	1.02	0.83 to 1.25	.86
Tertile 3 (> 89.5 kg)	0.85	0.67 to 1.07	.17